Market Place
Sourcing Support
Fresenius & Formycon Receive FDA Approval For Biosimilar Otulfi
30 Sep 2024 //
BUSINESSWIRE
Formycon`s Biologic Ahzantive (aflibercept-mrbb) Receives Approval in US
28 Jun 2024 //
FDA
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon
14 May 2024 //
PHARMIWEB
Formycon reports on successful operating business and financial
08 May 2024 //
PHARMIWEB
J&J`s Stelara settlement streak rolls on with Fresenius Kabi, Formycon deal
08 Aug 2023 //
FIERCE PHARMA
Broad-acting antiviral SARS-CoV-2 drug FYB207 shows longer improved efficacy
02 Nov 2022 //
PHARMIWEB
Formycon Publishes Details Of A Previously Undisclosed Pipeline Project – FYB206
19 Sep 2022 //
FORMYCON
European Commission approves pharma trio’s Ranivisio
30 Aug 2022 //
PHARMATIMES
FDA Approves First Biosimilar to Lucentis
03 Aug 2022 //
CONTRACTPHARMA
Who’s Hired? Formycon Is Latest To Swap CEO
20 May 2022 //
PHARMAINTELIGENCE
Teva Receives Approval for First Ophthalmology Biosimilar in Europe
20 May 2022 //
LEXBLOG
Formycon &Scientists from TUM publish new Data SARS-CoV-2 FYB207
09 Dec 2021 //
DGAP
DGAP-Adhoc: Formycon Concludes Collaboration and License Agreement with SCG
18 Oct 2021 //
BLOOMBERG
Formycon reports on the status of FYB207 development
11 Aug 2021 //
BLOOMBERG
Formycon & Bioeq announce submission of the BLA for FYB201
05 Aug 2021 //
PRESS RELEASE
Formycon and Bioeq Submitted marketing authorization application for FYB201
29 Jun 2021 //
FORMYCON
Formycon receives approval for early action for COVID-19 drug FYB207
27 Apr 2021 //
PHARMIWEB
FORMYCON RECEIVES POSITIVE SCIENTIFIC ADVICE FROM PAUL-EHRLICH
24 Feb 2021 //
FORMYCON
Formycon and Bioeq announce Launch of Phase III Study of FYB202, Stelara®
09 Nov 2020 //
PHARMIWEB
Formycon informs about the modified BLA-Submission Strategy for its Lucentis®
05 Nov 2020 //
YAHOO
Revance Therapeutics, Mylan, and Formycon Announce Updates
21 May 2020 //
BIGMOLECULEWATCH
Formycon Announces Update On Biosimilar Programs
15 May 2020 //
BIOSIMILARDEVELOPMENT
Formycon informs about the current Status of the BLA Review FYB201
04 Feb 2020 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.